Skip to main content
Signal8

ProMIS Neurosciences Inc. (PMN) Form 8-K — Nov 12, 2026

$PMNForm 8-KItems 2.02, 9.01Filed Nov 12, 2026, 4:17 PM ET0001104659-26-126260Original filing

ProMIS Neurosciences reported Q3 2026 results with a net loss of $8.2 million ($(0.89)/share) and reaffirmed that its PRECISE-AD Phase 1b trial of PMN310 in Alzheimer's disease remains on track for unblinded 12-month topline data in Q1 2027. The company highlighted encouraging blinded six-month interim data in 136 patients: zero ARIA-E events across all APOE genotypes, mild ARIA-H of 4.4%, and biomarker reductions of ~15% in plasma pTau217 and 13.3% in CSF MTBR-tau243. Cash of $44.1 million is expected to fund operations through 2027, beyond the data readout.

Key figures

Revenue
0
Cash Position
44100000
Aria h rate pct
4.4
Cash dec 31 2025
6116556
Q3 2025 net loss
11580126
Ga expense q3 2025
1953014
Ga expense q3 2026
1905389
Rd expense q3 2025
9797418
Rd expense q3 2026
6710035
Other income q3 2026
453556
Apoe4 homozygotes pct
11
Nine month net loss 2025
29045059
Nine month net loss 2026
28135897
Precise ad interim patients
136
Weighted avg shares q3 2026
9143340
Plasma ptau217 reduction pct
15
Csf mtbr tau243 reduction pct
13.3
Private placement net proceeds
70100000

AI analysis

Red flags2 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.

    ProMIS Neurosciences Inc. (PMN) Form 8-K — Nov 12, 2026: AI Analysis | Signal8